Sanofi Ambien patent
Executive Summary
Sanofi will list Ambien patent covering modified-release version of insomnia agent in FDA's "Orange Book," company says. Patent for zolpidem MR (no. 6,514,531) would run to 2019; Ambien exclusivity currently expires in 2006. Sanofi plans to file in 2004 for FDA approval (1"The Pink Sheet" Feb. 24, p. 15)...
You may also be interested in...
Sanofi Ambien Line Extension Planned For 2004; Still Confident In Arixtra
Sanofi-Synthelabo plans to file for approval of a modified-release formulation of the insomnia agent Ambien during the second quarter of 2004
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
World-First Nod For Yuhan's Lung Cancer Drug, In Korea
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: